Overexpression of HMGA2 promotes metastasis and impacts survival of colorectal cancers

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2570-2580

  Wang, Xiaochen ^a,b   Liu, Xiyong ^b   Li, Angela Ying Jian ^b   Chen, Lirong ^a   Lai, Lily ^b   Lin, Her Helen ^b   Hu, Shuya ^b   Yao, Lifang ^a   Peng, Jiaping ^a   Loera, Sofia ^b   Xue, Lijun ^b   Zhou, Bingsen ^b   Zhou, Lun ^a   Zheng, Shu ^a   Chu, Peiguo ^b   Zhang, Suzhan ^a   Ann, David Kong ^b   Yen, Yun ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH MOBILITY GROUP A2 PROTEIN; HISTONE H2AX;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GAMMA IRRADIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOSENSITIVITY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CELL LINE, TUMOR; COLON; COLORECTAL NEOPLASMS; FEMALE; HCT116 CELLS; HEK293 CELLS; HISTONES; HMGA2 PROTEIN; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 79954578408     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2542     Document Type: Article

References (40)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Lei T, Chen WQ, Zhang SW, Lei TH, Ying Q, He ZY, et al. [Prevalence trend of colorectal cancer in 10 cities and counties in China from 1988 to 2002]. Zhonghua zhong liu za zhi [Chin J Oncol] 2009;31:428-33.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
4. Lupinacci R, Penna C, Nordlinger B. Hepatectomy for resectable colorectal cancer metastases-indicators of prognosis, definition of resectability, techniques and outcomes. Surg Oncol Clin North Am 2007;16:493-506. (Pubitemid 46990949)
5. Cleynen I, Van de Ven WJ. The HMGA proteins: a myriad of functions (review). Int J Oncol 2008;32:289-305. (Pubitemid 351188295)
6. Fedele M, Battista S, Kenyon L, Baldassarre G, Fidanza V, Klein-Szanto AJ, et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene 2002;21:3190-8. (Pubitemid 34548089)
7. Sgarra R, Rustighi A, Tessari MA, Di Bernardo J, Altamura S, Fusco A, et al. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett 2004;574:1-8. (Pubitemid 39200885)
8. Monzen K, Ito Y, Naito AT, Kasai H, Hiroi Y, Hayashi D, et al. A crucial role of a high mobility group protein HMGA2 in cardiogenesis. Nature Cell Biol 2008;10:567-74. (Pubitemid 351627376)
9. Nishino J, Kim I, Chada K, Morrison SJ. Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression. Cell 2008;135:227-39.
10. Ashar HR, Chouinard RA Jr., Dokur M, Chada K. In vivo modulation of HMGA2 expression. Biochim Biophys Acta 2010;1799:55-61.
11. Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nature Rev 2007;7:899-910. (Pubitemid 350165857)
12. Sarhadi VK, Wikman H, Salmenkivi K, Kuosma E, Sioris T, Salo J, et al. Increased expression of high mobility group A proteins in lung cancer. J Pathol 2006;209:206-12. (Pubitemid 43805416)
13. Miyazawa J, Mitoro A, Kawashiri S, Chada KK, Imai K. Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res 2004;64:2024-9. (Pubitemid 38339449)
14. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A 2007;104:11400-5. (Pubitemid 47175152)
15. Langelotz C, Schmid P, Jakob C, Heider U, Wernecke KD, Possinger K, et al. Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. Br J Cancer 2003;88:1406-10. (Pubitemid 36606424)
16. Huang ML, Chen CC, Chang LC. Gene expressions of HMGI-C and HMGI (Y) are associated with stage and metastasis in colorectal cancer. Int J Colorectal Dis 2009;24:1281-6.
17. Liu X, Zhou B, Xue L, Shih J, Tye K, Lin W, et al. Metastasissuppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells. Clin Cancer Res 2006;12:6337-44. (Pubitemid 44799702)
18. Nguyen HV, Chen JL, Zhong J, Kim KJ, Crandall ED, Borok Z, et al. SUMOylation attenuates sensitivity toward hypoxia-or desferroxamineinduced injury by modulating adaptive responses in salivary epithelial cells. Am J Pathol 2006;168:1452-63.
19. Boo LM, Lin HH, Chung V, Zhou B, Louie SG, O'Reilly MA, et al. High mobility group A2 potentiates genotoxic stress in part through the modulation of basal and DNA damage-dependent phosphatidylinositol 3-kinase-related protein kinase activation. Cancer Res 2005;65:6622-30. (Pubitemid 41060698)
20. Li AY, Boo LM, Wang SY, Lin HH, Wang CC, Yen Y, et al. Suppression of nonhomologous end joining repair by overexpression of HMGA2. Cancer Res 2009;69:5699-706.
21. Fabjani G, Tong D, Wolf A, Roka S, Leodolter S, Hoecker P, et al. HMGA2 is associated with invasiveness but not a suitable marker for the detection of circulating tumor cells in breast cancer. Oncol Rep 2005;14:737-41.
22. Rogalla P, Drechsler K, Kazmierczak B, Rippe V, Bonk U, Bullerdiek J. Expression of HMGI-C, a member of the high mobility group protein family, in a subset of breast cancers: relationship to histologic grade. Mol Carcinog 1997;19:153-6. (Pubitemid 27360132)
23. Motoyama K, Inoue H, Nakamura Y, Uetake H, Sugihara K, Mori M. Clinical significance of high mobility group A2 in human gastric cancer and its relationship to let-7 microRNA family. Clin Cancer Res 2008;14:2334-40. (Pubitemid 351551065)
24. Kazmierczak B, Bullerdiek J, Pham KH, Bartnitzke S, Wiesner H. Intron 3 of HMGIC is the most frequent target of chromosomal aberrations in human tumors and has been conserved basically for at least 30 million years. Cancer Genet Cytogenet 1998;103:175-7. (Pubitemid 128712627)
25. Furuta S, Wang JM, Wei S, Jeng YM, Jiang X, Gu B, et al. Removal of BRCA1/CtIP/ZBRK1 repressor complex on ANG1 promoter leads to accelerated mammary tumor growth contributed by prominent vasculature. Cancer Cell 2006;10:13-24.
26. Arlotta P, Tai AK, Manfioletti G, Clifford C, Jay G, Ono SJ. Transgenic mice expressing a truncated form of the high mobility group I-C protein develop adiposity and an abnormally high prevalence of lipomas. J Biol Chem 2000;275:14394-400. (Pubitemid 30339724)
27. Battista S, Fidanza V, Fedele M, Klein-Szanto AJ, Outwater E, Brunner H, et al. The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res 1999;59:4793-7. (Pubitemid 29472878)
28. Bol S, Wanschura S, Thode B, Deichert U, Van de Ven WJ, Bartnitzke S, et al. An endometrial polyp with a rearrangement of HMGI-C underlying a complex cytogenetic rearrangement involving chromosomes 2 and 12. Cancer Genet Cytogenet 1996;90:88-90. (Pubitemid 26316430)
29. Geurts JM, Schoenmakers EF, Van de Ven WJ. Molecular characterization of a complex chromosomal rearrangement in a pleomorphic salivary gland adenoma involving the 30-UTR of HMGIC. Cancer Genet Cytogenet 1997;95:198-205.
30. Fedele M, Battista S, Manfioletti G, Croce CM, Giancotti V, Fusco A. Role of the high mobility group A proteins in human lipomas. Carcinog 2001;22:1583-91. (Pubitemid 32952135)
31. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007;21:1025-30. (Pubitemid 46686471)
32. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and HMGA2 enhances oncogenic transformation. Science 2007;315:1576-9. (Pubitemid 46449474)
33. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007;131:1109-23. (Pubitemid 350235025)
34. Fedele M, Visone R, De Martino I, Troncone G, Palmieri D, Battista S, et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell 2006;9:459-71. (Pubitemid 43832192)
35. Markowski DN, von Ahsen I, Nezhad MH, Wosniok W, Helmke BM, Bullerdiek J. HMGA2 and the p19Arf-TP53-CDKN1A axis: a delicate balance in the growth of uterine leiomyomas. Genes Chromosomes Cancer 2010;49:661-8.
36. Cunningham D, Atkin W, Lenz H-J, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet 2010;375:1030-47.
37. Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005;41:2060-70. (Pubitemid 41337947)
38. Fluge O, Gravdal K, Carlsen E, Vonen B, Kjellevold K, Refsum S, et al. Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis. Br J Cancer 2009;101:1282-9.
39. Robbins AS, Chen AY, Stewart AK, Staley CA, Virgo KS, Ward EM. Insurance status and survival disparities among nonelderly rectal cancer patients in the National Cancer Data Base. Cancer 2010;116:4178-86.
40. Summer H, Li O, Bao Q, Zhan L, Peter S, Sathiyanathan P, et al. HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy. Nucleic Acids Res 2009;37:4371-84.